GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atomo Diagnostics Ltd (ASX:AT1) » Definitions » LT-Debt-to-Total-Asset

Atomo Diagnostics (ASX:AT1) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Atomo Diagnostics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Atomo Diagnostics's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

Atomo Diagnostics's long-term debt to total assets ratio increased from Dec. 2023 (0.00) to Dec. 2024 (0.00). It may suggest that Atomo Diagnostics is progressively becoming more dependent on debt to grow their business.


Atomo Diagnostics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Atomo Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atomo Diagnostics LT-Debt-to-Total-Asset Chart

Atomo Diagnostics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24
LT-Debt-to-Total-Asset
- - 0.01 0.01 0.01

Atomo Diagnostics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - 0.01 -

Atomo Diagnostics LT-Debt-to-Total-Asset Calculation

Atomo Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (A: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2024 )/Total Assets (A: Jun. 2024 )
=0.057/11.379
=0.01

Atomo Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )/Total Assets (Q: Dec. 2024 )
=0.025/9.249
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atomo Diagnostics  (ASX:AT1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Atomo Diagnostics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Atomo Diagnostics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Atomo Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
3 - 5 George Street, Level 1, Leichhardt, Syndey, NSW, AUS, 2040
Atomo Diagnostics Ltd is an Australian medical device design innovator and original equipment manufacturing company. The company is engaged in the development and sale of medical devices. The company develops point-of-care devices for rapid diagnostic testing. The company offers AtomoRapid RDT Platform with devices including Galileo, Pascal, Curie, and Elion. The firm operates in a single segment, medical device research and development.

Atomo Diagnostics Headlines

No Headlines